Dallah Healthcare Co. · TADAWUL:4004
Dallah Healthcare — Q1 2025 Earnings Presentation
27 slides from Dallah Healthcare's earnings presentation, 2025
Slide 1: Dallah Healthcare Co. Q1-2025
Dallah Healthcare Co. Q1- 2025
Slide 2: Today's Speakers and Agenda
Today’s Speakers and Agenda 1. About us 2. Business Review 3. Financial Review Amine A.Hariz Omar Aljabari Saud Alraqraq Chief Financial Officer Chief Commercial Officer Business Development Director 1
Slide 3: DHC's mission and vision guided by core values
DHC’s mission and vision … … guided by core values Mission Values To deliver excellent healthcare services Care and respect for our patients, which are consistent with our values and their needs and our society with the expectation of our patients, society, and partners Commitment to professional et
Slide 4: Dallah Healthcare Company offers an attractive investment opportunity
DHC has long been established in KSA and has shown year-on-year growth DHC has a strong product portfolio, consistently growing to address the evolving needs of patients Dallah Healthcare Company offers an DHC has numerous certifications positioning it at the forefront in terms of service excellence
Slide 5: History: DHC has a long legacy in the healthcare space in KSA
Dallah Hospital- 1987 Al Nakheel Dallah Pharma 2002 Dallah Ob-gyne 2007 2012 DHC listing Dallah Pediatrics 2013 Jordanian Pharmaceuticals Co. Afyaa Al Nakheel 2014 and DMRF North clinics 2015 quite rapidly both organically and inorganically Dallah Hospital- 2018 Namar Dallah Al Nakheel Meras Arabia
Slide 6: DHC owns and directly operates five categories of companies
Dallah Health Company Portfolio Today, DHC owns and directly operates five categories of companies while also engaging in active management of portfolio investments Owned & operated by DHC Portfolio investments (ownership share, %) Hospitals Clinics Dr. MRF Hospital Fully equipped private hospital,
Slide 7: DHC's longstanding presence in KSA and integrated portfolio of services
12 +2,650 Healthcare Facilities Beds DHC’s longstanding presence in KSA and integrated portfolio of services position it +30% 48% Patients Volume CAGR Net Profit as a leader in service FY20-24 CAGR FY20-24 excellence, quality, and patient safety 5 +207 Medical specialities & sub- Cities arounk KSA s
Slide 8: Awards and Honours
“Ribbons 3” “Most Contributing Leading Hospital” By Newsweek (USA) in collaboration with CHI and Statista By CHI “The Joint Commission International “Excellence in Patient Satisfaction” (JCI) accreditation” Awards and Honours by the Global Patient Experience For Dallah Namar Hospital Organization “1
Slide 9: With +2,560 beds, DHC aims to further expand
Dallah Health Company Portfolio With +2,560 beds, DHC aims to further expand to meet future demand Combined current capacity at +2,560 beds across DHC's operational entities and investments Companies owned & operated by 540 300 475 274 3 2 beds beds beds beds Location Cities DHC Portfolio investment
Slide 10: Future Projects
Dallah Health Company Portfolio Future Projects Dallah Alarid Hospital Dallah Alnakheel Land Dallah Clinics • Land: 45,000 sqm • DHC, Dallah Real Estate, Aljazira Capital, • Built-up area: 87,300 sqm and Tatweer signed MoU to establish a private real estate fund. • 250 Beds • 3 Locations • An estima
Slide 11: DHC's presence over the Kingdom of Saudi Arabia
DHC's presence Al Khobar over the �)« Riyadh Al Hofouf Kingdom of ÷U�d�« ·uH�« Saudi Arabia Jeddah …b� Makkah W�dJ*« WJ� Abha UN�√ 10
Slide 12: Array of medical services offered by DHC hospitals
Dallah Health Company Portfolio The array of medical services offered by DHC hospitals extends across various specialties, complemented by supplementary support services 207+ Medical specialities and subspecialties 4+ key Ancillary Services Medical services under the following therapy areas: Supplem
Slide 13: Patient volume growth, Q1-24 vs Q1-25
Dallah Health Company Portfolio Over the past 5 years, DHC's hospitals have demonstrated consistent patient volume growth, a trend evident when comparing Q1-24 with Q1-25 Patient volume (in 000s) CAGR 7% 31% 2,839 2,737 2,252 1,800 968 692 739 2020 2021 2022 2023 2024 Q1-24 Q1-25 • MMC and KHCC was
Slide 14: Certifications, accreditations and awards for service excellence
Dallah Health Company Accreditations When addressing service excellence and patient safety, DHC has acquired several well-regarded certifications, accreditations, and awards One of the first hospitals in Dallah Hospital laboratory Dallah Hospitals catering Saudi Arabia awarded JCI certified by the C
Slide 15: DHC's Journey to Value-Based Healthcare
DHC’ Journey to Value-Based Healthcare DHC's is dedicated to leading the way in VBHC, ultimately delivering greater value and improved health outcomes for our patients Key initiatives: Pilot Programs Strategic Collaborations Future Focus • PROM & PREM with a Major Insurer • The Center for Value in H
Slide 16: DHC's future growth supported by well-defined 5-year strategy
Dallah Health Company Growth Strategy & Leadership DHC's future growth is supported by its well-defined 5-year strategy anchored around a coherent direction for the diversified portfolio Deep-dive included in the next slides Operating companies Investments Become a one-stop shop for VIP/A privately
Slide 17: Becoming a 'one-stop high-end' service provider
Dallah Health Company Growth Strategy & Leadership To become a 'one-stop high-end' service provider, DHC will selectively specialize as well as expand into clinics, telemedicine, post-acute care and homecare Value One-stop-shop high-end provider First point of contact from the cradle to the grave Pr
Slide 18: Financial performance growth between Q1-24 and Q1-25
Dallah Health Company Financial Performance Regarding its financial performance, DHC has experienced growth between Q1-24 and Q1-25 Key consolidated financial results (M SAR) Q1-24 Q1-25 Revenues 784 6% 833 EBITDA 195 19% 232 EBIT 159 17% 187 Net Profit 127 23% 157 Net Profit attributable to shareho
Slide 19: Revenues over 5 years (1/5)
Dallah Health Company Financial Performance The trend of financial growth extends since 2020 and is supported by DHC's financial results over 5 years (1/5) Revenues (M SAR) CAGR 6% 25% 3,206 2,943 2,488 2,105 784 833 1,318 2020 2021 2022 2023 2024 Q1-24 Q1-25 18
Slide 20: Gross Profit over 5 years (2/5)
Dallah Health Company Financial Performance The trend of financial growth extends since 2020 and is supported by DHC's financial results over 5 years (2/5) Gross Profit (M SAR) CAGR 1.4% 28% 1,600 1600 38% 40% 37% 40% 36% 36% 37% 36% 1,400 1400 34% 35% 35% 1,200 1200 1,207 30% 30% 1,000 1,079 1000 2
Slide 21: EBIT over 5 years (3/5)
Dallah Health Company Financial Performance The trend of financial growth extends since 2020 and is supported by DHC's financial results over 5 years (3/5) EBIT (M SAR) CAGR 17% 45% 1000 1000 25% 22% 900 900 21% 20% 800 19% 800 20% 700 17% 700 16% 16% 16% 600 600 15% 610 500 500 11% 504 400 11% 400
Slide 22: EBITDA over 5 years (4/5)
Dallah Health Company Financial Performance The trend of financial growth extends since 2020 and is supported by DHC's financial results over 5 years (4/5) EBITDA (M SAR) CAGR 19% 34% 1200 30% 1200 30% 28% 25% 1000 25% 1000 25% 23% 21% 21% 21% 800 20% 800 20% 18% 751 600 15% 600 15% 630 514 400 449
Slide 23: Net Profit over 5 years (5/5)
Dallah Health Company Financial Performance The trend of financial growth extends since 2020 and is supported by DHC's financial results over 5 years (5/5) Net Profit (M SAR) CAGR 23% 48% 800 800 19% 19% 19% 700 700 17% 16% 17% 15% 600 15% 600 15% 13% 13% 500 12% 13% 500 13% 485 11% 11% 400 400 385
Slide 24: Q1-25 is the second highest quarter ever in revenues
Dallah Health Company Financial Performance Q1-25 is the second highest quarter ever in terms of revenues Revenues (SAR M) 848 833 806 784 809 750 765 717 670 Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Q4-24 Q1-25 23
Slide 25: Debt-to-EBITDA ratio decreasing year on year
Dallah Health Company Financial Performance As for its debt-to-EBITDA ratio, DHC is pursuing YoY decreases through more informed capital allocation strategies during its expansion Debt-to-EBITDA (M SAR) 6.5x 4.2x 3.8x 3.0x 2.5x 2.5x 3.7x 2,890 1,935 1,895 1,897 1,867 1,840 1,515 751 751 774 630 449
Slide 26: Highest return on equity in the past 3 years
Dallah Health Company Financial Performance DHC achieved its highest return on equity in the past 3 years averaging between 12% to 14% Return on Equity (M SAR) 13.4% 13.7% 13.5% 13.4% 14% 12% 9.0% 2020 2021 2022 2023 2024 Q1-24 Q1-25 25
Slide 27: Thank you
Thank you